10x Genomics has launched a multi-year research collaboration with Cleveland Clinic to study bladder cancer using advanced single cell and spatial biology platforms. The goal is to identify biomarkers that predict patient responses to antibody-drug conjugates and immunotherapies, addressing the challenge of variable treatment outcomes. This work aims to improve diagnostic tools and personalize cancer treatment by analyzing tumor biology and microenvironment at high resolution. The collaboration will generate comprehensive data linking biological insights with clinical outcomes to advance oncology diagnostics.

More News (TXG)

Torex Gold appoints Andrew Snowden as CEO, approves name change to Torex Resources Inc.

Torex Gold Resources held its 2026 annual meeting, appointing Andrew Snowden as the new President and CEO following Jody Kuzenko's retirement. The company also re-elected seven directors and re-appointed Rick Howes as Board Chair. Shareholders approv...

Company Fundamentals

Bullish

3 days ago

10x Genomics partners with Cleveland Clinic to identify biomarkers predicting bladder cancer treatment response.

More News (TXG)

Torex Gold appoints Andrew Snowden as CEO, approves name change to Torex Resources Inc.

Invest & Trade with
#1 Award-Winning Investment Super App

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store

10x Genomics partners with Cleveland Clinic to identify biomarkers predicting bladder cancer treatment response.

More News (TXG)

Torex Gold appoints Andrew Snowden as CEO, approves name change to Torex Resources Inc.

Invest & Trade with#1 Award-Winning Investment Super App

iOS App Store

Google Play Store

Invest & Trade with
#1 Award-Winning Investment Super App